• Japanese
  • Korean
  • Chinese
Cover Image

Diabetes Therapeutics Market in India to 2018 - Rapid Uptake of DPP-IV Inhibitors, GLP-1 Agonists and Expanding Insulin Segment to Drive Growth

Summary

GBI Research, the leading business intelligence provider, has released its latest research "Diabetes Therapeutics Market in India to 2018 - Rapid Uptake of DPP-IV Inhibitors, GLP-1 Agonists and Expanding Insulin Segment to Drive Growth", which provides insights into the India anti-diabetes market until 2018. The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts. Insights into the diabetes epidemiology, cost of therapy, research and development pipeline and the promising molecules which are anticipated to be launched by 2018 are discussed in the report. The report provides an in-depth analysis type 1 and type 2 diabetes. The report provides an in-depth analysis on oral anti-diabetics agents, insulin products and drivers and barriers that could significantly impact the overall anti-diabetes market during the forecast period. Additionally, it explores the competitive landscape, including benchmarking the top companies in the market and the key issues and trends that are likely to have an impact on the Indian diabetes market during the forecast period. Finally, a key trend analysis for mergers and acquisitions and licensing agreements involving diabetes therapies is also discussed in the report.

GBI Research's analysis revealed that the overall anti-diabetes market in India was worth $680.3m in 2011 and is projected to grow at a CAGR of 11.3% between 2011 and 2018 to reach $1,446m in 2018. High and growing diabetes population in the country, rising obese and geriatric population, and rapid market adoption of drugs from the classes such as Dipeptidyl Peptidase 4 (DPP-4) inhibitors, Glucagon-Like Peptide (GLP)-1, Sodium-Glucose Transport Proteins (SGLT-1) and others would drive the anti-diabetes market in the forecast period. The R&D product pipeline for DM, dominated by OAD agents, consists of around 200 molecules at various stages of clinical development. Paradoxically, type 2 diabetes therapeutics market, crowded with many generics and branded generics drug products, is being seen as a significant growth opportunity for new patent protected products owing to high prevalence, progressive nature of the disease and considerably high unmet needs. Of overall R&D pipeline molecules, more than 90% are being studied for the treatment of type 2 DM.

Many multinational companies, such as Novartis, Eli Lilly, are engaged in setting up strategic marketing and distribution agreements with domestic players to improve their patient base and so the market share. Growing at a double digit year on year growth rate, the Indian anti-diabetics market is very promising and offers lucrative opportunities to both domestic as well as foreign pharmaceutical players.

Scope

  • Data and analysis on the Indian diabetes therapeutics market
  • Annualized market data for the diabetes therapeutics market from 2004 to 2011, with forecasts to 2018 for type 1 and type 2 diabetes.
  • Epidemiological data on type 1 and type 2 diabetes along with market size, annual cost of therapy, unmet needs and economic burden of diabetes.
  • Key drivers and restraints that have had a significant impact on the market.
  • Major trends and issues which are likely to have a significant impact on overall diabetes therapeutics market in India
  • Competitive landscape of the diabetes therapeutics market including top companies benchmarking. The key companies studied in this report are Novo Nordisk, Sanofi, Novartis, Eli Lilly, Merck, Abbott, USV, Sun Pharma, Biocon and Wockhardt.
  • Key M&A activities and licensing agreements, major deals that took place in last four years in Indian diabetes therapeutics market.

Reasons to buy

  • Align their product portfolio to the markets with high growth potential.
  • Build effective strategies to launch their pipeline products by identifying potential geographies.
  • Exploit in-licensing and out-licensing opportunities by identifying products that might fill their portfolio gaps.
  • Develop key strategic initiatives by studying the key strategies of top competitors.
  • Devise a more tailored country strategy through the understanding of key drivers and barriers and market potential.
  • Develop market-entry and market expansion strategies by identifying the geographic markets poised for strong growth.
  • Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules which are safer and more efficacious.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Diabetes Therapeutics Market in India to 2018-Overview

  • 2.1. Diabetes Mellitus-A Global Overview

3. Diabetes Therapeutics Market in India-Introduction

  • 3.1. Type 1 Diabetes Mellitus
    • 3.1.1. People at Risk
    • 3.1.2. Risk Factors for Type 1 Diabetes
    • 3.1.3. Symptoms
  • 3.2. Type 2 Diabetes Mellitus
    • 3.2.1. People at Risk
    • 3.2.2. Risk Factors for Type 2 Diabetes
    • 3.2.3. Symptoms
  • 3.3. Gestational Diabetes Mellitus
    • 3.3.1. Risk Factors for Gestational Diabetes Mellitus
  • 3.4. Diagnosis of Diabetes Mellitus
  • 3.5. Diabetes Treatment Guidelines-India
    • 3.5.1. Introduction
    • 3.5.2. Prevention of Diabetes
    • 3.5.3. Diabetes Treatment
  • 3.6. Diabetes Mellitus Complications

4. Diabetes Therapeutics Market in India to 2018-Major Drug Classes

  • 4.1. Sulfonylureas
    • 4.1.1. Introduction
    • 4.1.2. Mechanism of Action
    • 4.1.3. Major Drugs
  • 4.2. Thiazolidinediones
    • 4.2.1. Introduction
    • 4.2.2. Mechanism of Action
    • 4.2.3. Example
  • 4.3. Biguanides
    • 4.3.1. Introduction
    • 4.3.2. Mechanism of Action
    • 4.3.3. Drug Products
  • 4.4. Meglitinides
    • 4.4.1. Introduction
    • 4.4.2. Mechanism of Action
    • 4.4.3. Major Drugs
  • 4.5. Alpha-Glucosidase Inhibitors
    • 4.5.1. Introduction
    • 4.5.2. Mechanism of Action
    • 4.5.3. Major Drugs
  • 4.6. Glucagon-Like Peptide Analogs and Agonists
    • 4.6.1. Description
    • 4.6.2. Mechanism of Action
    • 4.6.3. Major Drugs
  • 4.7. Dipeptidyl Peptidase-4 Inhibitors
    • 4.7.1. Description
    • 4.7.2. Mechanism of Action
    • 4.7.3. Major Drugs
  • 4.8. Glucagon-Like Peptide-1 Analogs vs. Dipeptidyl Peptidase-4 Inhibitors
  • 4.9. Insulin Preparations
    • 4.9.1. Introduction
    • 4.9.2. Types of Insulin

5. Diabetes Therapeutics Market in India to 2018-Epidemiology

  • 5.1. Introduction
  • 5.2. Diabetes Population in India
  • 5.3. Diagnosed Population
  • 5.4. Treated Population

6. Diabetes Therapeutics Market in India to 2018-Revenue Forecasts

  • 6.1. Introduction
    • 6.1.1. Oral Anti-Diabetics Market
    • 6.1.2. Insulin Market
  • 6.2. Annual Cost of Therapy

7. Diabetes Therapeutics Market in India to 2018-Economic Burden of Diabetes in India

  • 7.1. Economic Burden of Diabetes in India
    • 7.1.1. Introduction
    • 7.1.2. Healthcare Expenditure on Diabetes in India
  • 7.2. Collaborative Efforts Necessary to Address the Rising Burden of Diabetes

8. Diabetes Therapeutics Market in India to 2018-Drivers and Barriers

  • 8.1. Market Drivers
    • 8.1.1. Aging Population, Sedentary Lifestyle and Unhealthy Diet is Driving the Diabetic Population in India
    • 8.1.2. Promising Molecules Offering Improved Clinical Outcomes Could Increase Patient Base on Therapy
    • 8.1.3. Untapped Areas Offer Promising Opportunities to Pharmaceutical Companies
  • 8.2. Market Barriers
    • 8.2.1. Low Diagnosis and Prescription Rate
    • 8.2.2. Highly Competitive Market Driven by Generics and Branded Generics Increases Pricing Pressure
    • 8.2.3. High Out-of-Pocket and Low Healthcare Expenditure on Diabetes

9. Diabetes Therapeutics Market in India to 2018-Unmet Needs

  • 9.1. Introduction
  • 9.2. High Cost of Therapy and Drug Safety Issues Affect Patient Compliance
  • 9.3. Unmet Need Creates Opportunities for Pharmaceutical Companies

10. Diabetes Therapeutics Market in India to 2018-Product Pipeline Analysis

  • 10.1. Profiles of Promising Molecules in R&D Development
    • 10.1.1. IN-105(Oral Insulin)
    • 10.1.2. NN9068/IDegLira/degludec +/- liraglutide
    • 10.1.3. Dapagliflozin
    • 10.1.4. Canagliflozin/TA-7284
    • 10.1.5. Lixisenatide
    • 10.1.6. Alogliptin

11. Diabetes Therapeutics Market in India to 2018-Case Studies

  • 11.1. Avandia Fallout Impact
    • 11.1.1. Introduction
    • 11.1.2. Cardiovascular Safety Issues
    • 11.1.3. Impact on GlaxoSmithKline
    • 11.1.4. Impact on Drug Approvals
  • 11.2. Januvia from Merck an Example that Patented Products can succeed in India
    • 11.2.1. Introduction
    • 11.2.2. Improved Pharmacological Effect of DPP-4 Inhibitors Helped Rapid Adoption
    • 11.2.3. Januvia and Janumet a New Growth Engine for Merck
    • 11.2.4. Robust Approach Needed to Market a New Drug Product in India
    • 11.2.5. Excellent Commercialization Strategy
    • 11.2.6. Conclusion

12. Diabetes Therapeutics Market in India to 2018-Major Trends and Issues

  • 12.1. Biguanides Class is dominated by Generics
  • 12.2. Evolving Oral Hypoglycemic Agents Resulting in Smaller Market Share Sulfonylureas
  • 12.3. Increasing Competition in Dipeptidyl Peptidase-4 Inhibitor Class
    • 12.3.1. DPP-4 Inhibitors Likely to Face Potential Competition from GLP-1 Agonists
  • 12.4. Thiazolidinedione Class to Face Impact of Avandia Fallout
  • 12.5. GLP-1 Agonists Must Demonstrate Better Safety and Efficacy Profiles to Compete with other Oral Hypoglycemic Class
  • 12.6. Fierce Competition in the Insulin Market is Likely to Increase
  • 12.7. Is Oral Insulin the Next Big Thing in the Insulin Market?
    • 12.7.1. Introduction
    • 12.7.2. Oral Insulin Not for All
    • 12.7.3. Challenges to Overcome
    • 12.7.4. Would it lead to Market Cannibalization?
  • 12.8. India Diabetes Market: Setting up for the Biosimilars?
    • 12.8.1. Introduction
    • 12.8.2. Insulin Biosimilar Market
    • 12.8.3. Sanofi's Lantus a Lucrative Target
    • 12.8.4. Need for Dose Adjustments would Discourage Uptake of Biosimilars
    • 12.8.5. Price Discounts Alone would be Insufficient
    • 12.8.6. Strong Brand Promotion would be Necessary for Insulin Biosimilars
    • 12.8.7. Collaborations and Licensing Agreements are Key
    • 12.8.8. Conclusion
  • 12.9. Sodium Glucose Co-Transporter2 Inhibitors: A New Class to Hit the Market?
  • 12.10. Glucokinase Activators
  • 12.11. Stem Cell Therapies: The Next Prospective Therapy for Diabetes?
    • 12.11.1. Introduction
    • 12.11.2. What are Stem Cells?
    • 12.11.3. Stem Cell Therapies and Diabetes
    • 12.11.4. Conclusion
  • 12.12. Price Discounts a Decisive Factor in the Increasingly Competitive Anti-Diabetes Market
  • 12.13. Favorable Government Polices to Promote Generics
  • 12.14. Strategic Consolidation to Increase Growth Prospects
    • 12.14.1. Introduction
    • 12.14.2. Shift of Focus towards Rural and Class II-IV Towns

13. Diabetes Therapeutics Market in India to 2018-Competitive Landscape

  • 13.1. Novartis India Limited (Novartis India)
  • 13.2. Novo Nordisk India Private Limited (Novo)
  • 13.3. Eli Lilly and Company (India) Pvt. Ltd. (Eli Lilly)
  • 13.4. Merck Sharp Dohme India
  • 13.5. Abbott India Limited (Abbott India)
  • 13.6. Sun Pharmaceutical Industries Limited (Sun Pharma)
  • 13.7. USV Limited
  • 13.8. Wockhardt Limited (Wockhardt)
  • 13.9. Sanofi India Limited
  • 13.10. Biocon Limited (Biocon)

14. Diabetes Therapeutics Market in India to 2018-Strategic Consolidations

  • 14.1. Introduction
  • 14.2. Diabetology Entered into Licensing Agreement with USV for Capsulin on July 31, 2012
  • 14.3. Merck Sharp & Dohme Entered into Co-Marketing Agreement with Sun Pharma on April 25, 2011
  • 14.4. Eli Lilly and Company (India) Entered into Co-Promotion Agreement with Lupin on July 29, 2011
  • 14.5. Sheffield Bio-Science Entered into Collaboration with Wockhardt on February 21, 2011
  • 14.6. Eli Lilly Entered into Co-Promotion Agreement with Boehringer Ingelheim for Humalog and Linagliptin on October 3, 2011
  • 14.7. Novartis India Entered into Co-Marketing Agreement with USV on December 31, 2008
  • 14.8. Pfizer-Biocon Deal Called Off in March 2012
    • 14.8.1. Impact Analysis

15. Diabetes Therapeutics Market in India to 2018-Appendix

  • 15.1. Market Definitions
  • 15.2. Abbreviations
  • 15.3. Bibliography
  • 15.4. Research Methodology
    • 15.4.1. Coverage
    • 15.4.2. Secondary Research
    • 15.4.3. Primary Research
  • 15.5. Therapeutic Landscape
    • 15.5.1. Market
  • 15.6. Geographical Landscape
  • 15.7. Pipeline Analysis
  • 15.8. Competitive Landscape
    • 15.8.1. Expert Panel Validation
  • 15.9. Contact Us
  • 15.10. Disclaimer

List of Tables

  • Table 1: Diabetes Market, India, Diagnosis, Blood Sugar Estimation and Interpretation, 2012
  • Table 2: Diabetes Market, India, Diagnosis, Oral Glucose Tolerance Test, Estimation and Interpretation (mg/dL), 2012
  • Table 3: Diabetes Market, India, Oral Hypoglycemic Agents, Sulfonylurea, 2012
  • Table 4: Diabetes Market, India, Oral Hypoglycemic Agents, Thiazolidinediones, 2012
  • Table 5: Diabetes Market, India, Oral Hypoglycemic Agents, Biguanides, 2012
  • Table 6: Diabetes Market, India, Oral Hypoglycemic Agents, Meglitinides, 2012
  • Table 7: Diabetes Market, India, Oral Hypoglycemic Agents, Alpha-glucosidase Inhibitors, 2012
  • Table 8: Diabetes Market, India, Treatment Usage Pattern (million), 2004-2011
  • Table 9: Diabetes Market, India, Treatment Usage Pattern (million), 2011-2018
  • Table 10: Diabetes Market, India, Anti-Diabetic Revenue ($m), 2004-2011
  • Table 11: Diabetes Market, India, Anti-Diabetic Revenue Forecast ($m), 2011-2018
  • Table 12: Diabetes Market, India, Annual Cost of Therapy ($), 2004-2011
  • Table 13: Diabetes Market, India, Annual Cost of Therapy Forecast ($), 2011-2018

List of Figures

  • Figure 1: Diabetes Market, India, Type 2 Diabetes Treatment Model, 2012
  • Figure 2: Diabetes Market, Global, Diabetes Prevalence, 2011
  • Figure 3: Diabetes Market, Global, Top 10 Diabetes Destinations, 2011
  • Figure 4: Diabetes Market, India, Diabetes Population (million), 2011
  • Figure 5: Diabetes Market, India, Treatment Usage Pattern (million), 2004-2018
  • Figure 6: Diabetes Market, India, Anti-diabetic Revenue Forecast ($m), 2004-2018
  • Figure 7: Diabetes Market, India, Annual Cost of Therapy ($), 2004-2018
  • Figure 8: Diabetes Market, India, Mean Diabetes-related Expenditure Per Person ($), 2011
  • Figure 9: Diabetes Market, India, Drivers and Barriers, 2012
  • Figure 10: Diabetes Market, India, Product Pipeline by Phase, 2012
  • Figure 11: Diabetes Market, India, Novartis India Limited, Diabetes Product Portfolio, 2012
  • Figure 12: Diabetes Market, India, Novo Nordisk, Diabetes Product Portfolio, 2012
  • Figure 13: Diabetes Market, India, Eli Lilly, Diabetes Product Portfolio, 2012
  • Figure 14: Diabetes Market, India, Merck Sharp Dohme, Diabetes Product Portfolio, 2012
  • Figure 15: Diabetes Market, India, Abbott India, Diabetes Product Portfolio, 2012
  • Figure 16: Diabetes Market, India, Sun Pharma, Diabetes Product Portfolio, 2012
  • Figure 17: Diabetes Market, India, USV Limited, Diabetes Product Portfolio, 2012
  • Figure 18: Diabetes Market, India, Wockhardt Limited, Diabetes Product Portfolio, 2012
  • Figure 19: Diabetes Market, India, Sanofi, Diabetes Product Portfolio, 2012
  • Figure 20: Diabetes Market, India, Biocon Limited, Diabetes Product Portfolio, 2012
  • Figure 21: GBI Research Market Forecasting Model
Show More
Pricing
  • Int'l: +1-860-674-8796
  • TollFree(US): +1-866-353-3335
  • Europe: +32-2-535-7543
  • Asia: +65-6223-2436
Back to Top